Probiotics mediated control and immunomodulation of SARS-CoV-2 associated pathological conditions

P. Saravana Kumari*, V. Viswapiyra, M. Lydia Rajakumari* and S. Murugan**
Department of Microbiology, Rathnavel Subramaniam College of Arts and Science, Coimbatore-641402, Tamil Nadu, India
*Department of Microbiology, Indira Gandhi College of Arts and Science, Kathirkamam, Puducherry-605209, India
**Department of Biotechnology, Karunya Institute of Technology and Sciences, Coimbatore-641114, Tamil Nadu, India

Article Info
Article history
Received 1 May 2021
Revised 16 June 2021
Accepted 17 June 2021
Published Online 30 June 2021

Keywords
Probiotics
SARS-CoV-2
Variants of SARS-CoV-2
Immunomodulation
Treatment of COVID-19
Mechanism of probiotics

Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a fast-evolving respiratory infection-causing virus. The simple structure of the virus enables it to spread through the air and easy lodging into the respiratory tract of the host. The virus-specific spike protein rendering antigenicity and pathogenicity in the host. The spike protein is highly evolving as an immunogenic form through mutation. Variants of the virus are much more pathogenic that induce inflammation during the early stages of infection and cytokine storm in later stages of infection, which cause cytolysis of own host cells. Drugs used are targeted towards spike protein and virus-specific components and several drugs are under trial. A drug that needs to control the host immune response and maintain homeostasis in the host is required. Anti-inflammatory drugs and steroids recommended for immunomodulatory and as immunosuppressors according to the prevailing condition of infection. Several phytomedicines evaluated for their efficiency to control the pandemic. Another natural system to control viruses is the probiotic organisms, proven for their ability to competitively inhibit entry and establishment of viral pathogens in the host. Administration of probiotics during the primary stage of viral infection improves the host immunity and prevents the increase in viral load and in later stages, regulates the host immunity when host immunoregulation disrupted by viral antigen. This helps in the immunomodulation of the host immune system on the whole. The present review evaluates the immunomodulatory effect of probiotics to control SARS-CoV-2.

1. Introduction
The coronavirus disease 2019 (COVID-19) has imposed major threat to the children, pregnant women, employees, executives, geriatric, patients with chronic complications, researchers and industries. It affected the teaching-learning process, availing necessary healthcare support at times and high risk of getting infection to the mother and infant, regular income, overall productivity and improvisation, psychological effect on safety and well-being, survival of patients with lung problem, hypertension and heart diseases, efficient technology to develop drugs and vaccines (required within short period) and challenged the scientist in mass production of drugs and vaccine to meet huge mass at a short stretch. A mild to moderate respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected all sectors of human life invariably. Prime mode of transmission is through air, as respiration is indispensable for all life, while respiring aerosols or droplets containing virus lead to the complications associated with COVID-19 infection and severe infection in persons with comorbidities. Coronavirus belongs to the family Coronaviridae, subfamily Nidovirales. A comprehensive taxonomic analysis of the viruses in the coronoviridae revealed that humans are the only host for SARS-CoV-2 (Evgeny et al., 2020). The first outbreak of COVID-19 and related respiratory sickness was reported in Wuhan, Hubei Province, China during December 2019. The rate of infections is very high and spread across the globe as pandemic. The World Health Organization (WHO) is to keep in track of this pandemic and disseminating relevant updated information continuously. Due to its severity in infection and the high rate of infection, the WHO on January 30, 2020 declared that the SARS-CoV-2 epidemic is a public health emergency of international concern (PHEIC). After that, WHO officially named SARS-CoV-19 infection in human as coronavirus disease-2019 (COVID-19) on February 11, 2020 and the International Committee on Taxonomy of Viruses (ICTV) named the virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The WHO reported that globally 162.7 million confirmed cases of COVID-19, including 3.3 million deaths on 17 May 2021 and around 1,264,164,553 vaccine doses administered to beneficiaries till 11 May 2021. The average number of transmission of SARS-CoV-2 from one infected person to another (R or R0) varied from 1.8 to 3.6 (average of 2.5) across the globe, comparatively higher than the recent pandemics of SARS-CoV (R-value 2.0 to 3.0) and influenza (R-value 1.5) (PeterSEN et al., 2020). Although, the R number across the UK is now between 0.7 and 0.9, in Scotland’s estimated R number is between 0.8 and 1.0, in Wales the number is between 0.6 and 0.9, Northern Ireland was 0.75 and 0.95, England, was between 0.8 and 1.0 and in India it is increased from 1.8 to 2.1 recently. Comparatively, the United States, India, and Brazil are the three countries with the largest cumulative number of confirmed cases in the world. Now, SARS-CoV-2 is recognized as the third

Corresponding author: Dr. P. Saravana Kumari
Associate Professor, Department of Microbiology, Rathnavel Subramaniam College of Arts and Science, Coimbatore-641402, Tamil Nadu, India
E-mail: sarankanuiris@gmail.com
Tel.: +91-9442386269

Copyright © 2021 Ukaaz Publications. All rights reserved.
Email: ukaaz@yahoo.com; Website: www.ukaazpublications.com
infection which is zoonotic in origin and transmitted to human of this century and affected a huge mass with 3.4% of mortality rate (Gralinski and Menachery, 2020).

2. Structure of SARS-CoV-2

Coronaviruses belong to the subfamily Coronavirinae in the family of Coronaviridae and belongs to the group beta coronavirus. The genome of SARS-CoV-2 is a single-stranded, linear, positive-sense RNA consists of 29903 nucleotides arranged in 14 open reading frames which is larger than any other RNA viruses (Ankur Das et al., 2021). Genetic material is coiled with phosphate and capsid protein to form nucleocapsid phosphoprotein (N) covered by an envelope which is associated with four structural proteins: membrane protein (M), spike glycoprotein (S), hemagglutininesterase dimer (HE) and envelope protein (E) coded by Orf 1 (266 to 21,555 nt), and sixteen non-structural proteins (nsp1 to 16 coded by Orf 3, 6, 7, 8, 9 and 10) (Tai et al., 2020) (Figure 1). Functions of nsp are nsp1 - inhibition of host mRNA translation and affects signals from IFN, nsp2-survival signaling pathway of host cell, nsp3 - separation of the translated protein, nsp4-transmembrane domain (TM2) and modifies ER membranes, nsp5-processing of polyprotein, nsp6-presumptive transmembrane domain, nsp7 and nsp8-increase the stable binding of nsp12 and template-primer 7SLRNA, nsp9-single stranded RNA-binding protein, nsp10-cap methylase domain, nsp11-5'-3' exoribonuclease domain, nsp12-3'-5' exoribonuclease domain, nsp13-ATP and the zinc-binding domain to participate in the replication and transcription, and nsp14-proofreading exoribonuclease domain, nsp15-Mn(2+)-dependent endoribonuclease polymerase (RdRp) for coronavirus replication/transcription, nsp15-binds with ATP and the zinc-binding domain to participate in the replication and transcription, and nsp15-endonucleases, nsp16 - 2'-O-ribose methyltransferase and host mRNA splicing (Naqv et al., 2020). Nsp1 binds to 18S ribosomal RNA in the mRNA entry channel of the ribosome to interfere with the translation of mRNA. Nsp9 and Nsp10 bind to the 7SL RNA which located at the ‘signal recognition particle’ to disrupt protein trafficking to the cell membrane (Banerjee et al., 2020).

Figure 1: Structure of SARS-CoV-2 proteins.

2.1 Santigen

Santigen or spike glycoprotein plays important role in recognition and attachment of virus to the host cells. It is a homotrimer S1, S2 and transmembrane segments. S1 consists of five antiparallelly arranged beta strands linked by disulphide bonds referred as N-terminal domain (NTD) or receptor binding domain (RBD) binds to angiotensin-converting enzyme-02 (ACE-2) receptor present on the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue of the human.

S2 subunit consists of a fusion peptide (FP), trimmers of heptad repeat 1(HR1), trimeric coiled - heptad repeat 2(HR2), central helix (CH), connector domain (CD), transmembrane domain (TM), and cytoplasmic tail (CT) which connects S1 domain with the virus. Proper folding of s-protein and neutralizing antibodies are associated with the glycans present on the S1 subunit and the whole domain protruded outside the virus during the time of infection (Wrapp et al., 2020). The HR1 and HR2 domains are linked by a hydrogen bond between lysine at 933 position in HR1 and asparagine at 1,192 position in HR2. Seventeen of the 20 residues of the ACE2 receptor interact with the RBD of SARS-CoV-2 with high affinity and forms a stable interaction the host (Figure 2).

Figure 2: Interaction of S-protein with ACE-2 receptor on cell membrane.

Transmembrane serine protease-2 (TMPRSS2) is a surface protein expressed on endothelial cell that is involved in activation of spike protein in SARS-CoV-2 along with furin. To activate the S1 protein, cleaved by furin protease present near the ACE-2 receptor. It cleave linking region between S1 and S2 subunit on the human cell. The furin cleavage site includes P681, R682, R683, and A684. Loss of these cleavage site completely affects the pathogenesis of the virus by loss of binding function with ACE-2 receptor (Wang et al., 2020). Emma et al. (2020) described a rapid rise of SARS-CoV-2 infections due to the substitution at position S:677 polymorphism of the S gene that lead to 6 distinct variants suggest a selective advantage of the virus to escape from immune system and drugs.

2.2 The RNA-dependent RNA polymerase (RdRp)

The replication and transcription of SARS-CoV-2 is mediated through a combination of viral nsp and RNA dependent RNA polymerase in nsp 12, 7 and 8 complex. The nsp 12 has N-terminal end with a unique hairpin loop and C-terminal end which are linked by an interface domain. The RNA-dependent RNA polymerase domain consists of fingers subdomain, a palm subdomain, and a thumb subdomain (Wang et al., 2020) (Figure 3). The subunit nsp12 binds with the first turn of RNA between thumb domains and fingers domains. The active site of palm subdomain contains five nsp12 motifs A-E. The nsp8 extensions use the positively charged residues to interact with the RNA backbones. The nsp8 as the “sliding poles”, slide on the protruding RNA to prevent RdRp from dissociating prematurely during replication. The triphosphate-binding site is
conserved. Residues D623, S682, and N691 are interacts with the 2’-OH group of triphosphate (NTP), making the RdRp special for the synthesis of RNA (Wang et al., 2020).

2.3 The main protease

The main protease (Mpro) of SARS-CoV-2 plays a pivotal role in mediating the replication and transcription of viral gene. Inactive form of RdRp, nsp-13 and polyproteins (pp1a and pp1ab that is between nsp-4 and nsp-6) required for viral replication are cleaved by Mpro at eleven conserved sites. It belongs to the group cysteine protease with an active site contains cysteine and serine dyad and a water molecule. This has 99% of identity with bat coronavirus RaTG13 main protein. It is a homodimer of protomer A and protomer B, and each protomer contains 3 subdomains: domain I, domain II, and domain III. Domain II and domain III are linked by a loop and at the cleft between domain I and domain II lies the substrate-binding pocket (Jin et al., 2020).

Drugs used to control SARS-CoV-2 mainly aims at targets like viral spike protein (S), RNA-dependent RNA-polymerase (RdRp, nsp12), main protease, NTPase/helicase (nsp13) and papain-like protease (PLpro, part of nsp3) which are essential for viral replication/transcription and entirely different from human cellular component.

Table 1: SARS-CoV-2 variants and their adaptive advantages

| Variant and origin | Spike protein substitutions | Adaptive advantages in the variants |
|--------------------|-----------------------------|-------------------------------------|
| B.1.526 (United States) | Spike: (L5F), T95I, D253G, (S477N), (E484K), D614G, (A701V) | ● Reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment (fact sheet).  
● Reduced neutralization by convalescent and post-vaccination sera. |
| B.1.526.1 (New York) | Spike: D80G, 144, F157S, L452R, D614G, (T791I), (T859N), D950H | ● Potential reduction in neutralization by monoclonal antibody treatments. |
| B.1.525 (United Kingdom / Nigeria) P.2 (Brazil) | Spike: A67V, 69/70, 144, E484K, D614G, Q677H, F888L  
Spike: E484K, (P655L), D614G, V1176F | ● Potential reduction in neutralization by convalescent and post-vaccination sera. |
| B.1.1.7 (United Kingdom) | 69/70, 144, (E484K), (S494P), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N) | ● ~ 50% increased transmission (Davies et al., 2021).  
● Potential increased severity based on hospitalizations and case fatality rates (Horby et al., 2021).  
● No impact on treatment with monoclonal antibody treatments (Fact sheet).  
● Minimal impact on neutralization by convalescent and post-vaccination sera. |
| P.1(Japan/Brazil) | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027 | ● Significant decrease in susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment, but other monoclonal antibody treatments are available (Fact sheet).  
● Reduced neutralization by convalescent and post-vaccination sera (Emary et al., 2021). |
| B.1.427 (United States - California) | L452R, D614G | ● ~20% increased transmissibility (Deng, et al., 2021).  
● Modest decrease in susceptibility to the combination of bamlanivimab and etesevimab; however, the clinical implications of this decrease are not known. Alternative monoclonal antibody treatments are available.  
● Reduced neutralization by convalescent and post-vaccination sera (Liu et al., 2021). |
| B.1.429 (United States - California) | S13I, W152C, L452R, D614G | ● ~20% increased transmissibility (Deng, et al., 2021).  
● Modest decrease in susceptibility to the combination of bamlanivimab and etesevimab; however, the clinical implications of this decrease are not known. Alternative monoclonal antibody treatments are available.  
● Reduced neutralization by convalescent and post-vaccination sera. |
3. Variants of SARS-CoV-2
A variant is the organism having one or more mutations that differentiate it from other variants of a species. Globally, the SARS-CoV-2 variant having D614G mutation in the spike (S)-protein predominant strain. First recognized variant undergone S-D614 (aspartate) mutated to S-G614 (glutamine). Similar mutants of virus like particles of SARS-CoV-2 produced by mutation in M, N, E, and S proteins. This had increased infection rate of the mutant (Table 1). When mutation frequency of SARS-CoV-2 is calculated, it undergoes mutation at one or two single-nucleotide per genome in a month which is 50% of rate of mutation of flu virus and 25% of AIDS virus mutation rate and the overall mutation rate is slow compared to other RNA viruses. A novel exoribonuclease (ExoN) coded by virus helps in correcting the errors during genome replication. Even though, the major adaptive mechanisms rendered by these mutations are:

- Specific genes to affect transmission, diagnostics, therapeutics, or host immune responses.
- Increased level of outbreak by antigenic variants.
- Significant reduction in vaccine effectiveness or very low vaccine-induced protection.
- Severe pathological condition (hyperoxia) and increased mortality.

3.1 S protein mutations in SARS-CoV-2 variants
Mutations in the S gene, region responsible for pathogenesis and normal function (such as the receptor binding domain (RBD) or furin cleavage site) or activation of the S protein, are of the greatest interest. These mutations may provide an avenue for the virus to escape from immunity to the original SARS-CoV-2 strain. First reported mutation in S-protein at site D614G and the mutant has increased infectivity by assembling more functional S protein into the virion (Zhang et al., 2020). D614G is a substitutional mutation at 614 position of S protein by replacement of aspartate (D) with glycine (G) that enhanced viral replication in human lung epithelial cells and primary human airway tissues by increasing infectivity and stability of virions (Plante et al., 2021).

Novel variant of SARS-CoV-2 is B.1.1.7, commonly referred to the U.K. strain, variant B.1.351 known as 501Y.V2 or the South African variant, P.1., is known as 501Y.V3 or the Brazilian variant; B.1.427 and B.1.429 (Zhang et al., 2021), CAL.20C or the California variant recognized as B.1.526, or the New York variant and multiple lineages of variants that contain mutations at amino acid position 677 (CDC, 2021). SARS-CoV-2 variants have undergone major mutation in cleavage site, in B.1.1.7 substituted from proline (P) to histidine (H) at position 681, B.1.351 and B.1.526 both have undergone an alanine (A) to valine (V) substitution next to the furin cleavage site at 701. A base substitution recorded at the position L452R in B.1.526.1, B.1.427, and B.1.429 also another substitution of at E484K is present in B.1.525, P.2, P.1, and B.1.351, but only some strains of B.1.526 and B.1.1.7. B.1.1.7 variant is associated with increased risk of death compared to other variants (Weisblum et al., 2020) (Figure 4). Similar amino acid changes in the spike protein of B.1.1.7, B.1.351, P.1., B.1.427/B.1.429 and B.1.526 SARS-CoV-2 variants were recorded.

Figure 4: Amino acid changes in the spike (S) protein of SARS-CoV-2 variants.
Source: American Society for Microbiology (Ashley Hagen, 2021).
Alteration in antigenicity attributed by the deletion of amino acids in the position 69 and 70 mutation in the N-terminal S subunit of S protein cause a conformational change in the spike protein and the emergence of B.1.1.7 variant. Deletion of amino acid 144 in B.1.1.7 and amino acids 242-244 in B.1.351 decreased the binding ability of the virus with neutralizing antibodies (By Kevin et al., 2021).

Substitution of aspartate with glycine at position 253 that appears in B.1.526, helps to escape from monoclonal antibodies against the NTD, and L18F, a leucine (L) to phenylalanine (F) substitution at position 18 in P.1 and R246d variants, an arginine (R) to isoleucine (I) substituted at position 246 in B.1.351.

B.1.427/B.1.429 and B.1.526 also recognized to have amino acid substitutions in the NTD (Ashley Hagen, 2021).

3.2 RBD site variants

The receptor binding domain (RBD) of S protein is comprised of amino acids 319-541 and it directly binds to ACE2 receptors. Therefore, mutations in this portion affects the antigenicity. The variants B.1.1.7, B.1.351 and P.1 have replacement of asparagine (N) with tyrosine (Y) at position 501 of the RBD, which results in reduced antibody production and binding to RBD (Vipin Vashistha, 2021).

Variants B.1.351 and P.1 have RBD mutations in common, K417N or K417T, a lysine (K) to asparagine (N) or threonine (T) substitution at position 417, and E484K, a glutaminate (E) to lysine (K) substitution at position 484, that increases the affinity of RBD for ACE2, resistance to antibody neutralization, and antibody mediated therapy. The California strain B.1.427 and B.1.429, both contain the same 3 S gene mutations. One of these, L452R, is a substitution that replaces leucine (L) with arginine (R) at position 452 and increased the affinity of RBD and cause severe infection (Meredith Wadman, 2021).

3.3 Furin cleavage site variants

Mutation in furin cleavage site of S protein affects activation of virus to attach with the host cell. B.1.1.7 variant has a proline (P) to histidine (H) substitution at position 681 near the furin cleavage site.

B.1.351 and B.1.526 have an alanine (A) to valine (V) substitution at position 701 (A701V) that is still of which are of unknown function. Rapid rise in mutation at furin cleavage site resulted in emergence of 6 distinct variants having substitutional mutation at 677 position of furin cleavage site of s protein. Histine at 677 position substituted with glutamine (Q677H) in B.1.2, B.1.234, B.1.1.220 and B.1.1.222 and other two variant showed presence of proline substituted glutamine at 677 position (Q677P). Increasing spread rate of these variants and infectivity proven that these mutations cause high potential functional relevance in cell entry and deliberate an advantage in spread or transmission (Hodcroft et al., 2021).

3.4 C-terminal variants

S helps in binding of spike protein with host cell membrane also undergoes multiple mutation effects in efficient binding with host or of unknown function. The variants B.1.1.7 and P.1 have multiple mutations in the C-terminal domain of unknown significance.

4. Mechanism of pathogenesis by SARS-CoV-2

Biopsy of SARS-CoV-2 infected patients showed diffused alveolar sac and wall with the formation of hyaline membranes, mononuclear cells, and infiltration of macrophages in the filtrating air spaces. Presence of large number of viral particles were observed in the bronchial and type 2 alveolar epithelial cells under electron microscopy. In addition, spleen atrophy, lymph node necrosis, focal haemorrhage in the kidney, enlarged liver with inflammatory cell infiltration, oedema, and scattered degeneration of the neurons in the brain recorded in severely ill patients by autopsy suggesting multiple organs dysfunction (China National Health Commision, 2020 and Yao et al., 2020). However, there are no reports about broad dissemination of the viral particles by autopsy. Gastrointestinal tract and kidney cells expressing ACE-2 receptors also infected by SARS-CoV-2.

*Source: Yesudhas et al., 2021 (CC).
molecules, like adaptor molecule MyD88. Stimulatory molecules further activates transcription factors like nuclear factor-κB (NF-κB) and interferon regulatory factor 3 (IRF3) and helps in nuclear translocation. In the nuclei, these transcription factors induce the production of type I interferons (IFN-α/β) and a plethora of pro-inflammatory cytokines especially IL-6 (Li et al., 2020). Type I IFN suppress viral replication and promote phagocytosis of antigens by macrophage, as well as NK cells mediated restriction of infected cells (Zhou et al., 2020).

Generally, Th1 mediated immune response plays a predominant role in T cell responses that depend upon the presence of APC (antigen presenting cells) mediated cytokine microenvironment. CD8+ cytotoxic T cells (CTLs) secrete granzymes, perforin, and IFN-γ lyse the virus infected host cell and eradicate it. CD4+ Helper T cells induce the T cytotoxic cells and on the other hand, B-cell mediated humoral immune response. Through, the clonal propagation method induce the production of memory B cells and plasma cell against the each viral antigen to produce neutralizing antibody and prevent from further infection (Figure 5). Similar to SARS and MERS infection an elevated level of chemokines and plasma cytokines such as interleukins (IL-1, IL-2, IL-4, IL-7, IL-10, IL-12, IL-13, and IL-17), IP-10, macrophage colony-stimulating factor (MCSF), MCP-1, GCSF, hepatocyte growth factor (HGF), IFN-β, MIP-1α, and TNF-α, etc., are expressed from the virus infected cells referred as lymphopenia or cytokine storm (Moore and June, 2020) (Figure 6).

**Cytokine Storm** is due to the deregulated and excessive immune responses that cause damage to the host body. The cytokine storm cause the severe cytolysis of organs (air sac/lung/kidney/spleen/intestinal tract) and further viral infection such as acute respiratory distress syndrome (ARDS), pneumonitis, respiratory failure, sepsis shock, organ failure, and potentially death. Severity of COVID-19 in patients cause decrease in the number of circulating B cells, CD8+ cells, CD4+ cells, natural killers (NK) cells, and a decrease in eosinophils, monocytes, and basophils (Zhou et al., 2020). Apoptosis of endothelial cells and epithelial cells damages the pulmonary microvascular and alveolar epithelial cell barriers and causes vascular leakage and alveolar edema, eventually leading to hypoxia (oxygen deprived condition in the tissues). In severe case of ARDS innate immunity cause induction of hypoxia inducible factor-1α (HIF-1α) that cause up-regulation of vascular endothelial growth factor (VEGF). These factor induce the improper immune response by nonspecific inflammatory cell infiltration with increased vascular permeability leads to autophagy recruitment (Jahani et al., 2020). Autophagic recruitment cause blood (hypoxemia) and tissue (hypoxia) oxygenation plays major role in inflammation, capillary damage, organ failure and death due to collapse of lungs and cardiac arrest (Ostergaard, 2021). The cytokine storm is also a cause of death in ICU patients by increase the level of liver enzymes in gastrointestinal tract and creatinine levels in kidney that lead to extrapulmonary multiple-organ failure (Ye et al., 2020).

Figure 6: Immune response to SARS-CoV-2 infection in human body (Chatterjee et al., 2020).

In vitro cell experiments report that delayed release of cytokines and chemokines occurs in respiratory epithelial cells, dendritic cells (DCs), and macrophages at the early stage of SARS-CoV-2 infection completely arrest the host antiviral response in the host cells and induce inflammation. Later, the cells secrete low levels of the antiviral factors such as interferons (IFNs) and high levels of proinflammatory cytokines (interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)) and chemokines (C-C motif chemokine ligand (CCL-2, CCL-3, and CCL-5).

Delayed release of IFNs in the early stages of SARS-CoV and MERS-CoV infection hinders the body’s antiviral response (Channappanavar et al., 2019). Accelerated cytokine storm was also recognized and recorded in animal models such as mice, primates. In endothelial
cell line model the production of IFN-αβ and IFN-γ induced inflammatory cell infiltration through mechanisms involving Fas-Fas ligand (FasL) or tral-death receptor 5 (DR5) and cause the apoptosis of airway and alveolar epithelial cells (Rodrigue et al., 2014).

5. Treatment

Treatment for the COVID-19 infection developed by following two strategies: aimed to restrict or block the activity of the specific viral component or modulating host immune response. Again host immune response modulated in two different ways for treatment: boosting immune response during initial stage of the infection and suppress the immune response during later/high inflammatory stage of the infection. Many of the drugs are primarily targeted towards inactivation of virus specific components such as spike protein, nsp, RdRp, nucleocapsid phosphoprotein, RBP, inhibitors to 3-chymotrypsin like protease (3CLpro), etc. Different drug components are already in use against SARS-CoV newly developed drugs/drugs under development are targeted towards the SARS-CoV-2. The following table brief on drug candidates and their function (Table 2).

### Table 2: Drugs used for treatment of SARS-CoV-2 infection

| Drug of choice                          | Mechanism of action                           | Outcome                                                                 | References                        |
|----------------------------------------|------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------|
| IFN-α                                   | Activates epithelial cells and reduces the mononuclear macrophage-mediated proinflammatory activity of IFN-αβ inhibits the recruitment of neutrophils to the sites of inflammation activates the antiviral genes in epithelial cells | Early administration reducing viral load | Davidson et al., 2016             |
| Corticosteroid (Dexamethasone)          | Suppress inflammation                          | Treatment during initial period of infection reduced the mortality rate. But later cases caused increased severity of infection large doses delay the clearance of virus due to immunsuppression | Auyeung et al., 2005; Yam et al., 2007 |
| Passive immunization with IgG (casuruvumab/imdevimab) | immune substitution and immunomodulation | Effective on original strain neutralization but not on variants | Shakoory et al., 2016; Fischer et al., 2020 |
| Blockers of VEGP (e.g., bevacizumab)   | Suppress the expression of VEGF and reduce vascular permeability | Under clinical trials | Leah Shaffer, 2020 |
| Blockers of IL-1 (e.g., anakinra)       | Reduce the cytokine storm                      | Improved survival rate of patients with severe symptoms | Biggioggero et al., 2018 |
| Blockers of IL-6 (e.g., tocilizumab)   | Reduce the cytokine storm in severely infected persons | Improvise the severely inflamed organs | Tanaka et al., 2016 |
| Blockers of TNF                         | Blocks the receptors to bind with TNF          | Recommended during later stages of infection. Prevent from lung damage. Still need to explore | McDermott et al., 2016 |
| Inhibitor of IFN-αβ                    | Prevent from inflammation                      | Administered only later stages of the infection to reduce excessive inflammatory responses | Davidson et al., 2015             |
| Chloroquine                             | Inhibits the production of TNF and IL-6        | suppress the cytokine storm | Gao et al., 2020 |
| Hydroxychloroquine                     | Reduces the viral load during early stage of infection | Effect is enhanced by Azithromycin administration | Gautret, et al., 2020             |
| Ulinastatin                             | Natural anti-inflammatory                      | Protects the vascular endothelium Reduce cytokine storm | Wang et al., 2019 |
| Inhibitors of oxidised phospholipids (OxPL) | Reduces the production of inflammatory chemokines and cytokines | Reduce the rate of acute lung injury | Imai et al., 2008 |
| Antagonist to sphingosine - 1 phosphate receptor | Prevent the synthesis of cytokines               | Reduces proinflammatory responses in lungs | Walsh et al., 2011; Teijaro et al., 2011 |
| Mesenchymal stem cell therapy | Inhibit abnormal activation of Th1 cells and innate immune cells | Alleviate ARDS | Ucelli et al., 2015 |
|-------------------------------|---------------------------------------------------------------|---------------|-------------------|
| Blood dialysis                | Block cytokine storm and reduce the risk of inflammation     | Used to treat severely ill patients | Xu. K., et al., 2020 |
| Inhibitors of macrophage recruitment (siRNA) | Completely reduces the inflammation | Not clinically proven in COVID-19 patients/animal models | Leuschner et al., 2015 |
| Ivermectin                   | Binding and destabilizing cell transport proteins            | Still studies are going on. | Leah Shaffer, 2020 |
| Remdesivir                   | Inhibitor of RdRp                                             | Reduces the viral load in the lung | Wang et al., 2020 |
| Lopinavir                     | Inhibitor of viral protease -3-chymotrypsin-like protease     | Used along with ritonavir | Chen et al., 2006 |
| Famotidine                   | May bind to papain-like protease                             | Prevent the entry of virus into cell | Freedberg et al., 2020 |
| Nafamostat                   | Serine protease inhibitors (TMPRSS2)                         | Inhibit viral cell entry | Markus Hoffmann et al., 2010 |
| Blood thinners/anticoagulants | Heparin or warfarin. Prevent coagulation of blood by SARS-CoV-2 | Reduced the risk of blood coagulation. Still research need to be done | COVID-19 treatment guidelines panel |

6. Probiotics in control of SARS-CoV-2

Though, several drugs and natural components used for the treatment of COVID-19, the major role of human natural flora, friendly bacteria - probiotics their role in COVID-19 infection need to be elucidated. A potential therapy to block the multiplication of live organisms by other living organisms can be used to ensure continuous monitoring and regulation in the entry of pathogens into the body. The gastrointestinal tract of the human body includes bacteria, viruses, and fungi (Shi et al., 2017). The number of organisms varies from $10^9$ to $10^10$ CFU/millimeter of the small intestine and $10^11$ CFU/gram of lumen content of the colon (Thomas et al., 2017). Major gut probiotic microbiome includes *Lactobacillus acidophilus*, *L. casei*, *L. paracasei*, *L. rhamnosus*, *L delbrueckii* subsp. *bulgaricus*, *L. brevis*, *L. johnsonii*, *L. plantarum*, *L. fermentum*, *Saccharomyces boulardii*, *Bifidobacterium bifidum*, *Lactococcus lactis*, etc. The probiotic microbial population in the gut comprises 90% of *Firmicutes* and *Bacteroidetes* followed by other *Proteobacteria* and *Actinobacteria* (Rimininella et al., 2019).

Previous clinical studies reported that probiotics prevent bacterial and viral infections, including gastroenteritis, sepsis, and respiratory tract infections especially highly active in controlling 80% of respiratory tract infections caused by respiratory syncytial virus, rhinoviruses and influenza viruses (Baud et al., 2020). The major proposed mechanism used to control SARS-CoV-2 by the probiotics includes (Al Kassaa et al., 2014):

i. Interaction of probiotics directly inhibit virus lodging in the host system
ii. Production of various antiviral metabolites
iii. Immunomodulation of host

6.1 Competitive inhibition

Enriching the gut with probiotic population competitively inhibits the virus loading and multiplication in the gut. The virus propagates and establishes in the host gut when dysbiosis of probiotic population. Administration of probiotic organisms cause gut mediated-pulmonary immunity in virus-infected host system and reclaim health (Gohil et al., 2021). Antagonism of probiotics on the virus and its immunomodulatory function ameliorated by the mixed consumption of probiotics with prebiotics (Ollimma et al., 2020). Probiotics reported to competitively inhibit HIV adsorption to the host by the production of sulfated exopolysaccharides and by surfactin produced by *Bacillus subtilis* OKB105 inhibits adsorption by transmissible gastroenteritis virus. Well-known entry and attachment site of the SARS-CoV-2 manipulated by the presence of well flourished probiotic community and has attracted as a potential therapeutic target for a number of diseases. In COVID-19 infection, probiotics exert pressure on the expression of angiotensin converting enzyme 2 (ACE-2) in the small bowel and colon and prevent gut inflammation (Segal et al., 2020). Establishment of SARS-CoV-2 in the gut region reported replacing the beneficial probiotic bacteria (*Eubacterium ventriosum*, *Faecalibacterium prausnitzii*, etc.) with opportunistic pathogens (*Clostridium hathewayi*, *Actinomyces israelii*, *Bacteroides nordii*). Further complications associated with viral infections enhanced by these opportunistic pathogens. Other physical factors which complicate the health of COVID-19 patients include old age, heart diseases, obesity, hypertension and diabetes mellitus (uptake of associated medicines) leads todusbiosis of probiotics, which contribute to the severity of infection (Mak et al., 2020).

6.2 Antiviral metabolites

Probiotic organisms produce various metabolites that inhibit the establishment of viruses in the host. Biosurfactants are surface-active molecules that disrupt the lipid envelope of the virus. Similarly, fermentation end products such as organic acids (butyric acid/ lactic acid) produced by the probiotic organism prevent the actuality of the virus in the gut and down-regulate the intestinal permeability by the virus. Production of butyric acid energies the intestinal colonocyte which in turn constricts the integrity at tight junction where SARS-CoV-2 attachment to the gut epithelial cells and colonization becomes challenging (Baud et al., 2020). Metabolites from *Lactobacillus plantarum* such as plantaricin, lactic acid...
acid, acetic acid, and gamma-aminobutyric acid showed antiviral activity by binding with the virus and prevent it from associating with host system. Molecular docking studies reported that complete detention of binding of RBD and spike protein with ACE-2 by the probiotic metabolite plantaricin BN, plantaricin JLA-9, and plantaricin D. The maximum binding energies obtained with plantaricin W recorded as -14.64, 11.1 and 12.68 for polymerase, RBD and ACE2. Plantaricin W, D, and JLA-9 were able to block the residues (THR556, ALA558) surrounding the catalytic site (VAL557) of RdRp in SARS-CoV-2. So, the potential of plantaricin to control SARS-CoV-2 established with *in silico* model (Anwar *et al.*, 2020).

![Figure 7: Immune mechanism to control SARS-CoV-2 by probiotics.](image)

### 6.3 Immunomodulation

The probiotics are proven for their immunomodulatory effect upon viral infections in the human. Experimental data confirmed the increase in T helper cell-mediated immune response in influenza virus-infected parenchymal cells by *Lactobacillus* sp., and *Bifidobacterium* sp. Induction of phagocytosis of virus infected cells and increased innate immunity by the production of IL-4, IL-10, and IL-6 recorded in bronchoalveolar lavage by the *L. rhamnosus* and *B. lactis*. Clinical trials on the effect of probiotics in the management of SARS, MERS and SARS-CoV-2 need to be explored (Sundararaman *et al.*, 2020). The probiotic organisms modulate the gut and lung by entering into the lymphatic system. From the mesenchyme lymphatic system moves to the lung lymphatic system and modulates the immunity of the host. Actually, major sites of multiplication of SARS-CoV-2 in the host are the lung and gut. Immunomodulation in these regions certainly affects the pathogenicity of the virus. In the early stage of viral infection, inflammation and poor immune response result in severe pathological condition, in later stages excess of the immune response or cytokine storm leads to a sudden collapse in the host. Both immunological conditions are well maintained by the probiotic immunomodulatory function. First of all, probiotics enhance innate immunity by the cytolytic activity of macrophages, monocytes, neutrophils, natural killer cells, and allied cytokines to destroy the virus-infected cells. Secondly, by immunostimulatory task, activates the specific T-cells to induce cytotoxic activity and inflammatory mediators. Next by immunoregulation, triggers the specific neutralizing antibody production, meantime regulates the excess/uncontrolled expression of cytokines by treg mediators such as Th2, dendritic cells, and monocytes. Also regulate the inflammation, induction of IFN-g enhance B cell-mediated adaptive immunity and complement fixing antibodies (Figure 7). By the induction of treg mediators such as IL-25 migration of lymphoid cells from the gut to the lungs to dislodgement of pathogens recorded (Huang *et al.*, 2018). *Bifidobacteria* recognized to have the potential to ameliorate the viral cytokine storm through regulated expression of pro and anti-inflammatory cytokines (Hüseyin *et al.*, 2020).
Theoretical studies and experimental data of other viral infections concluded that probiotic bacteria may catalyze immune homeostasis during coronavirus infections (Singh and Rao, 2021). Thus, the probiotics function as live neurtacuteral and life-saving immunomodulatory from infections caused by SARS-CoV-2 and its variants. Also recommended that in absence of efficient treatment strategy, probiotics also used parallel with other treatment method (Gohil et al., 2021). Still, clinical studies on the mechanism of action of probiotics in vivo condition needs to be established in COVID-19 patients.

7. Future prospects
SARS-CoV-2 is the variant of the SARS virus, drastically affecting human society and the economy. The virus is mutating at a faster rate and adapting to escape from drugs that are used for treatment. Similarly, already developed vaccines reported to have less efficacy in combating the viral variants. The 86% efficiency of Covishield vaccine towards the wild type strain reduced to less than 63% on B.1.1.7 variant, 5% reduction in the efficacy of Novavax vaccine reported on variants (89%) versus non-variant strain (84%), and Astra Zeneca vaccine efficacy reduced from 84% on non-variant to 74% on variant strains. A ten-fold efficacy reduction in Pfizer and Moderna vaccine, 40% reduction of efficacy of Novavax against South African variant reported. Moreover, in the city of Manaus, Brazil about 70% of the persons already infected by the wild type strain of SARS-CoV-2 and acquired natural immunity toward the virus. But, records shows that again vaccinated individuals infected by the variant of SARS-CoV-2. These study results envisaged the inefficacy of natural immunity and acquired immunity (through vaccines) to prevent infections caused by variants. As the number of vaccines and drugs are developing, parallel variants also emerging. So, a live immune booster that continuously enhances the host immunity and competitively inhibits the entry of the virus can assure the remedy to viral infection. Also, pathological viruses cannot be eradicated by a single mechanism such as by administration of drug or vaccine as the virus is showing phase shift. An immunomodulator along with drugs or vaccines can complement the activity and eradicate the virus and its variants. An exploratory in vivo studies required to address the full proof of concept on the immunomodulatory effect of probiotic to control SARS-CoV-2.

Conflict of interest
The authors declare that there are no conflicts of interest relevant to this article.

References
Al Kassas, I.; Hoher, D.; Hamza, M.; Chihbi, N.E. and Drider, D. (2014). Antiviral potential of lactic acid bacteria and their bacteriocins. Probiot Antimicrob Proteins, 6:177-185. Doi: 10.1007/s12602-014-9162-6.

Ankur Das, Raja Ahmed; Suraiya Akhtar; Khaleda Begum and Sofia Banu (2021). An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies, Gene Reports, 23:101-122. Doi: 10.1016/j.genrep.2021.101122.

Anwar, F.; Altayh, H.N.; Al-Abbas, F.; Al-Malki, A.L.; Kamal, M.A. and Kumar, V. (2020). Antiviral effects of probiotic metabolites on COVID-19 (published online ahead of print, 2020 Jun 9). J. Biomol. Struct. Dyn., pp.1-10. doi:10.1080/07391102.2020.1775123

Ashley Hagen, M.S. (2021). American Society for Microbiology. SARS-CoV-2 Variants vs. vaccines. American Society for Microbiology. March 2021. https://asm.org/Articles/2021/February/SARS-CoV-2-Variants-vs-Vaccines.

Auyeung, T.W.; Lee, J.S.W.; Lai, W.K.; Choi, C.H.; Lee, H.K. and Lee J.S. (2005). The use of corticosteroid as treatment in SARS was associated with adverse outcomes: A retrospective cohort study. J Infect., 51(2):98-102. PubMed PMID: 16038758.

Banerjee, A.K.; Blanco, M.R.; Bruce, E.A.; Honson, D.D.; Chen, L.M. and Chow, A. (2020). SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell, https://doi.org/10.1016/j.cell.2020.10.004.

Boggiogero, M.; Crotti, C.; Becciolini, A. and Favalli, E.G. (2018). Tocilizumab in the treatment of rheumatoid arthritis: An evidence-based review and patient selection. Drug Design, Devel Therapy, 13:57-70. PubMed PMID: 30587928.

BioRxiv (2020).10.17.343749; doi: https://doi.org/10.1101/2020.10.17.343749. This article is a preprint and has not been certified by peer review.

By Kevin, R. Mccarthy; Linda, J. Rennick; Sham Nambusilli; Lindsey R. Robinson-Mccarthy; William G. Bain; Ghady Haidar, V. and Paul Dupres. (2021). Recurrent deleletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science, 12:1139-1142.

By Yan Guo; Liming Yan; Yacen Huzang; Fengjiang Liu. and Yao Zhao. (2020). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science, 28:779-782.

Center for Disease Control (2020). Science Brief: Emerging SARS-CoV-2 Variants. News, January 28:2021.

Channappanavar, R.; Fehr, A. R.; Zheng, J.; Wohlford-Lenane, C.; Abrahante, J. E.; Mack, M.; Sompallae, R. and McCray, P. B. (2019). IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. The Journal of Clinical Investigation, 129(9):3625-3639. https://doi.org/10.1172/JCI126363.

Chatterjee, S. K; Saha, S. and Munro, M. N. M. (2020). Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front. Mol. Biosci., 7:196. doi: 10.3389/fmolb. 2020. 00196.

Chen, R.C.; Tang, X.P.; Tan, S.Y.; Liang, B.I.; Wan, Z.Y. and Fang, J. Q. (2016). IFN-gamma is a potent anti-influenza therapeutic without the adverse outcomes: A retrospective cohort study. J Infect., 51(11):1619-1629. doi:10.1016/j.jinf.2020.07.070.

China National Health Commision (2020). Diagnosis and treatment of novel coronavirus pneumonia in China (trial version7).https://www.who.int/docs/default-source/prod-documents/countries/china/covid-19-briefing-nhc-1-clinical-protocols-for-the-diagnosis-and-treatment-of-covid-19-v7.pdf?sfvrsn=cc6cb4a_4

Chowdhury, M.A; Hossain, N.; Kashem, M.A.; Shahid, M.A. and Alam, A. (2020). Immune response in COVID-19: A review. J. Infect. Public Health, 13(11):1619-1629. doi:10.1016/j.jiph.2020.07.070.

COVID-19 Treatment Guidelines Panel (2021). Coronavirus disease 2019 (COVID-19). Treatment guidelines. National Institutes of Health. available at https://www.covid19treatmentguidelines.nih.gov/. accessed (23rd April 2021).

Davidson, S.; Maini M.K. and Wack A. (2015). Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J. Interf Cytokine Res. Offic J. Int. Soc. Interf Cytokine Res, 35(4):252-264. PubMed PMID: 25714109.

Davidson, S.; McCabe, T.M.; Crotta, S.; Gad, H.H.; Hessel E.M. and Beinke S. (2020). IFNy is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Molecul. Med. 8(9):1099-1112. Pub. Med., PMID:27520969.
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. MedRxiv. doi: 10.1101/2020.12.24.20248522.

Deng, X.; Garcia-Knight, M.A. and Khalid, M.M. (2021). Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. MedRxiv 2021. doi: https://doi.org/10.1101/2021.03.07.21252647.

Emery, K.R.W.; Golubchik, T. and Aley, P.K. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7). The Lancet, doi: http://dx.doi.org/10.2139/ssrn.3779160.

Emma, B. Hodercoh; Daryl B. Domman; Daniel J. Snyder; Kasoepofuluwa Y. Oguntayo; Maarten Van Diest and Kenneth H. Denosome. (2021). Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677. Medrixi. BMJ.medRxiv 2021. 02.12.21251658; doi: https://doi.org/10.1101/2020.02.12. 21251658.

Evgeny, V. Marvodieiev; Melinda L. Tursky; Nicholas E. Marvodieiev; Malte C. Ebach; David M. Williams; and Riboviria: Nidovirales. (2020). On classification and taxonomy of coronaviruses coronaviridae with the special focus on severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). bioRxiv. doi:10.1101/2020.10.17.343749.

Fact Sheet For Health Care Providers. (2020). Emergency use authorization (Eua) of bamlanivimab and etesevimab 02092021 (fda.gov) external icon.

Fischer, J.C.; Zänker, K.; van Griensven, M. (2020). The role of passive immunization in the age of SARS-CoV-2: An update. Eur. J. Med. Res., 25(16) 2020. https://doi.org/10.1186/s40001-020-00414-5.

Freedberg, D. E.; Conigliaro, J.; Wang, T. C.; Tracey, K. J.; Callahan, M. V.; and Abrams, J. A. (2020). Famotidine research group. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology.159(3):1129-131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22. PMID: 32446698; PMCID: PMC7242191.

Gao, J.; Tan, Z. and Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioci. Trends, 4:72-73.

Gautret, P.; Lagier, J.C.; Parola, P.; Huong, V.T.; Meddeb, L.; Mailhe, M.; Douard, B.; Courjon, J.; Giordanengo, V.; and Vieira, V.E. (2020). Hydroxychloroquine and azithromycin as a treatment of pneumonia in clinical studies. Biosci. Trends, 14(1):72-73. doi:10.1002/bstt.25685.

Grieco, J.; Barchis, J.; Krause, R.; and Zhang, Z. (2020). COVID-19: An update on pathogenesis and is blocked by a clinically proven protease inhibitor. Cell, 181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052.

McDermott, J.E.; Mitchell, H.D.; Granilski, I.E.; Eifeld, A.J.; Jostet, L. and Bankhead A. (2016). The effect of inhibition of PPI and TNFα signaling on pathogenesis of SARS coronavirus. BMC Syst. Biol., 10(1):93.

Meredith Wasman (2021). California coronavirus strain may be more infectious - and lethal. Health, coronavirus. Science., 2021. doi:10.1126/science.abb2101.

Moore, J.B. and June, C.H. (2020). Understanding the role of the microbiome in coronavirus infections post-SARS: Update on pathogenesis and impact of SARS-CoV-2 lineage B.1.1.7. MedRxiv 2021. doi: https://doi.org/10.1101/2021.03.07.21252647.

Naqvi, A.A.T.; Fatima, K.; Mohammad, T.; Fatima, U.; Singh, I. K. and Singh, A. (2020). Antioxidative stress and toll-like receptor 4 basis. International Journal of Immunopathology and Pharmacology, 01:516-22. https://doi.org/10.1186/s40001-020-00414-5.

NerVTAG: J.; Zänker, K.; van Griensven, M. (2020). The role of passive immunization in the age of SARS-CoV-2: An update. Eur. J. Med. Res., 25(16) 2020. https://doi.org/10.1186/s40001-020-00414-5.

Olaimat, A.N.; Aolymat, I. and Al-Holy, M. (2020). Identification of oxidative stress and toll-like receptor 4 basis. International Journal of Immunopathology and Pharmacology, 01:516-22. https://doi.org/10.1186/s40001-020-00414-5.

Ong, G.; Zeng, W.; Tian, L.; He, X.; Qian, H.; and Liu, Y. (2020). Novel coronavirus pneumonia (NCP) from SARS-CoV-2 and discovery of its inhibitors. Nature, 582:289-293. doi: 10.1038/s41586-020-2223-y.

Parkman, P.; Horby, P.; Koopmans, M.; Go, U.; Hamer, D.H.; Petrosillo, N.; Castelli F.; Storgard, M.; and Simonson, L. (2020). The Lancet Infectious Diseases, 20(9):e238-e244.

Plante, J.A.; Liu, Y. and Liu, J. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 592:116-121. https://doi.org/10.1038/s41586-020-2895-3.

Jahani, M.; Dosekanefarid, S. and Mansouri, K. (2020). Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm. J. Inflamm., 17:33 https://doi.org/10.1186/s12950-020-00263-3.

Jin, Z.; Du, X.; Xu, Y.; Deng, X.; Liu, M. and Zhao Y. (2020). Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature, 582:289-293. doi: 10.1038/s41586-020-2223-y.
Cellular inhibitor of apoptosis protein variant in Southern JAMA, 13:1324-1326. doi:10.1001/jama.2021.
spike protein variantsexternal icon. 11. J. Infect., 1:23-
of 2019 novel coronavirus: Structure, biology, and structure-based therapeutics. Development. Front. Cell. Infect. Microbiol., 10:587269. doi: 10.3389/fcimb.2020.587269.
Wang, H.; Yang, P.; Liu, K.; Guo, F.; Zhang, Y. and Zhang, G. (2008). SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res., 18:290-301. doi: 10.1038/cr.2008.15
Weisblum, Y.; Schmidt, F. and Zhang, F. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variantexternal icon. external icon. eLife 2020;9:e06132.
Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Heo, C. L. and Ahlborn, O. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Sci.(N.Y.N.Y.), 367:1260-1263. doi: 10.1126/science.abb2507.
Xu, K.; Cai, H.; Shen, Y.; Ni, Q.; Chen, Y.; Hu, S.; Li, J.; Wang, H.; Yu, L.; Huang, H.; Qiu, Y.; Wei, G.; Fang Q; Zhou, J.; Sheng, J.; Liang, T. and Li, L. (2020). Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(1):147-157. Chinese. doi: 10.3785/j.issn.1008-9292.2020.02.02. PMID: 32096367.
Yam, L.Y.C.; Lau, A.C.W.; Lai, F.Y.L.; Shung, E.; Chan, J. and Wong, V. (2020). Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J. Infect., 54(1):28-39. PubMed PMID: 16542729. Epub 2006/03/15.
Xiao, H.; Li, T. Y. and He, Z.C. (2020). A pathological report of three COVID-19 cases by minimally invasive autopsy. Zhonghua Bing Li Xue Za Zhi., 49[in Chinese].: E009
Ye, Q.; Wang, B. and Mao, J.(2020). The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J. Infect., 89(6):607-613. doi: 10.1016/j.jinf.2020.03.037.
Zhang, W.; Davis, B. D.; Chen, S. S.; Sineu Martinez, J. M.; Plummer , J. T. and Vail, E. (2021). Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA, 325(13):1324-1326. doi: 10.1001/jama. 2021. 1612
Zhang, L.; Jackson, C.B. and Mou, H. (2020). SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun., 11:6013 https://doi.org/10.1038/s41467-020-19808-4.
Zhou, Z.; Ren, L.; Zhang, L.; Zhong, J.; Xiao, Y. and Jia, Z. (2020). Heightened innate immune responses in the respiratory tract of COVID-19 Patients. Cell Host Microbe, 27:883-890.e2. doi: 10.1016/j.chom.2020.04.017.